Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q1 FY24 results · Apr–Jun 2023
Gufic Biosciences reported revenue from operations of ₹195.02 crore (up 18.0% from Q1 FY23) and net profit of ₹20.62 crore (down 2.0% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a standalone basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 195.02 | 165.28 | +18.0% | 173.04 | +12.7% |
| Other income | 0.88 | 0.37 | +135.2% | 0.62 | +41.4% |
| Total income | 195.90 | 165.65 | +18.3% | 173.66 | +12.8% |
| Profit before tax | 28.05 | 28.28 | −0.8% | 23.93 | +17.2% |
| Net profit for the period | 20.62 | 21.05 | −2.0% | 18.11 | +13.9% |
| EPS, basic (₹) | 2.13 | 2.17 | −1.8% | 1.87 | +13.9% |
| Net margin (%) | 10.6 | 12.7 | 10.5 |
Standalone
- Filed with BSE
- 11 Aug 2023, 17:43 IST
- Board meeting
- 11 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE